NO322614B1 - Indolyl-3-glykosylsyrederivater som har terapeutisk verdifulle egenskaper - Google Patents

Indolyl-3-glykosylsyrederivater som har terapeutisk verdifulle egenskaper Download PDF

Info

Publication number
NO322614B1
NO322614B1 NO20021367A NO20021367A NO322614B1 NO 322614 B1 NO322614 B1 NO 322614B1 NO 20021367 A NO20021367 A NO 20021367A NO 20021367 A NO20021367 A NO 20021367A NO 322614 B1 NO322614 B1 NO 322614B1
Authority
NO
Norway
Prior art keywords
acid
glyoxylamide
indol
pyridin
fluorobenzyl
Prior art date
Application number
NO20021367A
Other languages
English (en)
Norwegian (no)
Other versions
NO20021367L (no
NO20021367D0 (no
Inventor
Bernd Nickel
Juergen Engel
Gerald Bacher
Erik Bruyneel
Guenter Kam
Kirsten Peters
Thomas Beckers
Thomas Klenner
Peter-Paul Emig
Original Assignee
Baxter Healthcare Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19946301A external-priority patent/DE19946301A1/de
Application filed by Baxter Healthcare Sa filed Critical Baxter Healthcare Sa
Publication of NO20021367D0 publication Critical patent/NO20021367D0/no
Publication of NO20021367L publication Critical patent/NO20021367L/no
Publication of NO322614B1 publication Critical patent/NO322614B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20021367A 1999-09-28 2002-03-19 Indolyl-3-glykosylsyrederivater som har terapeutisk verdifulle egenskaper NO322614B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19946301A DE19946301A1 (de) 1998-04-02 1999-09-28 Indolyl-3-glyoxylsäure-Derivate mit therapeutisch wertvollen Eigenschaften
PCT/EP2000/009390 WO2001022954A2 (de) 1999-09-28 2000-09-26 Indolyl-3-glyoxylsäurederivate als antitumormittel

Publications (3)

Publication Number Publication Date
NO20021367D0 NO20021367D0 (no) 2002-03-19
NO20021367L NO20021367L (no) 2002-05-22
NO322614B1 true NO322614B1 (no) 2006-11-06

Family

ID=7923485

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20021367A NO322614B1 (no) 1999-09-28 2002-03-19 Indolyl-3-glykosylsyrederivater som har terapeutisk verdifulle egenskaper

Country Status (32)

Country Link
EP (1) EP1218006B1 (cs)
JP (1) JP2003510274A (cs)
KR (1) KR100759242B1 (cs)
CN (1) CN1301712C (cs)
AR (1) AR025885A1 (cs)
AT (1) ATE459356T1 (cs)
AU (1) AU783436B2 (cs)
BG (1) BG106639A (cs)
BR (1) BR0014378A (cs)
CA (1) CA2386069C (cs)
CZ (1) CZ303246B6 (cs)
DE (1) DE50015879D1 (cs)
DZ (1) DZ3196A1 (cs)
EE (1) EE200200169A (cs)
ES (1) ES2342042T3 (cs)
GE (1) GEP20043250B (cs)
HK (1) HK1048941B (cs)
HR (1) HRP20020369A2 (cs)
HU (1) HUP0202788A3 (cs)
IL (2) IL148670A0 (cs)
IS (1) IS6319A (cs)
MX (1) MXPA02002824A (cs)
NO (1) NO322614B1 (cs)
NZ (1) NZ517988A (cs)
PL (1) PL199576B1 (cs)
RS (1) RS51302B (cs)
RU (1) RU2282444C2 (cs)
SK (1) SK287533B6 (cs)
TW (1) TWI269654B (cs)
UA (1) UA75872C2 (cs)
WO (1) WO2001022954A2 (cs)
ZA (1) ZA200202556B (cs)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19962300A1 (de) * 1999-12-23 2001-06-28 Asta Medica Ag Substituierte N-Benzyl-Indol-3-yl-glyoxylsäure-Derivate mit Antitumorwirkung
WO2001092224A1 (en) 2000-05-31 2001-12-06 Astrazeneca Ab Indole derivatives with vascular damaging activity
DE10037310A1 (de) * 2000-07-28 2002-02-07 Asta Medica Ag Neue Indolderivate und deren Verwendung als Arzneimittel
EP1484329A1 (de) * 2003-06-06 2004-12-08 Zentaris GmbH Indolderivate mit Apoptose induzierender Wirkung
EP1595878A1 (de) * 2004-05-15 2005-11-16 Zentaris GmbH Indolderivate mit Apoptose induzierender Wirkung
AU2004245198B2 (en) * 2003-06-05 2009-04-23 Zentaris Gmbh Indole derivatives with apoptosis-inducing effect
US20050124623A1 (en) 2003-11-26 2005-06-09 Bender John A. Diazaindole-dicarbonyl-piperazinyl antiviral agents
EP1751115A4 (en) * 2004-05-23 2010-10-20 Gerard M Housey THERAMUTEINMODULATOREN
AU2005304952B2 (en) * 2004-11-08 2013-04-04 Baxter Healthcare S.A. Nanoparticulate compositions of tubulin inhibitors
US20060100432A1 (en) 2004-11-09 2006-05-11 Matiskella John D Crystalline materials of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-ethane-1,2-dione
WO2006073973A2 (en) 2004-12-31 2006-07-13 Reddy Us Therapeutics, Inc. Novel benzylamine derivatives as cetp inhibitors
US8604055B2 (en) 2004-12-31 2013-12-10 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
US7851476B2 (en) 2005-12-14 2010-12-14 Bristol-Myers Squibb Company Crystalline forms of 1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-YL)-1-[(phosphonooxy)methyl]-1H-pyrrolo[2,3-C]pyridin-3-YL]-1,2-dioxoethyl]-piperazine
US7807671B2 (en) 2006-04-25 2010-10-05 Bristol-Myers Squibb Company Diketo-piperazine and piperidine derivatives as antiviral agents
US20080241274A1 (en) * 2006-11-28 2008-10-02 Ziopharm Oncology, Inc. Indibulin therapy
MX2014001849A (es) 2011-08-18 2014-10-24 Reddys Lab Ltd Dr Compuestos de amina heterociclicos sustituidos como inhibidores de proteina de transferencia de ester colesterilo (cetp).
EP2760864B1 (en) 2011-09-27 2018-01-24 Dr. Reddy's Laboratories Ltd. 5-BENZYLAMINOMETHYL-6-AMINOPYRAZOLO[3,4-b]PYRIDINE DERIVATIVES AS CHOLESTERYL ESTER-TRANSFER PROTEIN (CETP) INHIBITORS USEFUL FOR THE TREATMENT OF ATHEROSCLEROSIS
US9353150B2 (en) 2012-12-04 2016-05-31 Massachusetts Institute Of Technology Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment
AU2014228822A1 (en) 2013-03-15 2015-10-01 Memorial Sloan-Kettering Cancer Center HSP90-targeted cardiac imaging and therapy
WO2017197045A1 (en) 2016-05-11 2017-11-16 Movassaghi Mohammad Convergent and enantioselective total synthesis of communesin analogs
US11932650B2 (en) 2017-05-11 2024-03-19 Massachusetts Institute Of Technology Potent agelastatin derivatives as modulators for cancer invasion and metastasis
CN109111501B (zh) * 2017-06-23 2022-04-22 首都医科大学 脂肪氨基酸修饰的吲哚乙醇衍生物, 其合成，活性和应用
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
WO2020247054A1 (en) 2019-06-05 2020-12-10 Massachusetts Institute Of Technology Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
WO2022182415A1 (en) 2021-02-24 2022-09-01 Massachusetts Institute Of Technology Himastatin derivatives, and processes of preparation thereof, and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4128089A (en) 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
RU2047603C1 (ru) * 1991-12-09 1995-11-10 Матвей Абрамович Рехтер 1-алкил-2-ацилиндолы и способы их получения
NZ314207A (en) * 1992-09-28 2000-12-22 Vertex Pharma 1-(2-Oxoacetyl)-piperidine-2-carboxylic acid derivatives as multi drug resistant cancer cell sensitizers
JP3163631B2 (ja) * 1992-10-20 2001-05-08 東レ株式会社 好酸球浸潤抑制剤
DE19636150A1 (de) * 1996-09-06 1998-03-12 Asta Medica Ag N-substituierte Indol-3-glyoxylamide mit antiasthmatischer, antiallergischer und immunsuppressiver/immunmodulierender Wirkung
WO1998045431A1 (fr) 1997-04-08 1998-10-15 Banyu Pharmaceutical Co., Ltd. Gene associe a la metastase cancereuse
TR200002447T2 (tr) * 1998-02-25 2000-11-21 Genetics Institute, Inc. Fosfolinaz enzimlerinin inhibitörleri
HUP0102612A2 (hu) * 1998-03-12 2001-11-28 Novo Nordisk A/S Fehérje-tirozinfoszfatázokat moduláló vegyületek és ezeket tartalmazó gyógyászati készítmények
DE19814838C2 (de) * 1998-04-02 2001-01-18 Asta Medica Ag Indolyl-3-glyoxylsäure-Derivate mit Antitumorwirkung
SI1076657T1 (en) * 1998-04-28 2004-12-31 Elbion Ag New hydroxyindoles, their use as phosphodiesterase 4 inhibitors and method for producing same
JP2000239252A (ja) * 1999-02-16 2000-09-05 Mitsubishi Chemicals Corp インドール誘導体
WO2000067802A1 (en) * 1999-05-10 2000-11-16 Protarga, Inc. Fatty acid-n-substituted indol-3-glyoxyl-amide compositions and uses thereof

Also Published As

Publication number Publication date
BG106639A (bg) 2002-12-29
ATE459356T1 (de) 2010-03-15
DZ3196A1 (fr) 2001-04-05
IL148670A0 (en) 2002-09-12
HK1048941A1 (en) 2003-04-25
NZ517988A (en) 2004-10-29
RU2282444C2 (ru) 2006-08-27
CN1301712C (zh) 2007-02-28
CN1376064A (zh) 2002-10-23
CZ20021005A3 (cs) 2004-01-14
KR100759242B1 (ko) 2007-09-18
HUP0202788A3 (en) 2003-02-28
WO2001022954A2 (de) 2001-04-05
AU783436B2 (en) 2005-10-27
HUP0202788A2 (hu) 2003-01-28
MXPA02002824A (es) 2003-07-21
NO20021367L (no) 2002-05-22
EE200200169A (et) 2003-04-15
SK287533B6 (sk) 2011-01-04
EP1218006A2 (de) 2002-07-03
BR0014378A (pt) 2003-07-29
JP2003510274A (ja) 2003-03-18
CA2386069C (en) 2012-08-14
SK4072002A3 (en) 2003-11-04
AR025885A1 (es) 2002-12-18
IS6319A (is) 2002-03-21
GEP20043250B (en) 2004-06-25
PL364811A1 (en) 2004-12-13
WO2001022954A3 (de) 2002-03-28
KR20030019295A (ko) 2003-03-06
NO20021367D0 (no) 2002-03-19
CZ303246B6 (cs) 2012-06-20
HK1048941B (zh) 2007-09-21
IL148670A (en) 2009-09-01
ZA200202556B (en) 2003-08-27
RS51302B (sr) 2010-12-31
CA2386069A1 (en) 2001-04-05
TWI269654B (en) 2007-01-01
EP1218006B1 (de) 2010-03-03
UA75872C2 (en) 2006-06-15
HRP20020369A2 (en) 2004-12-31
DE50015879D1 (de) 2010-04-15
AU7782900A (en) 2001-04-30
ES2342042T3 (es) 2010-07-01
PL199576B1 (pl) 2008-10-31
YU22702A (sh) 2004-12-31

Similar Documents

Publication Publication Date Title
NO322614B1 (no) Indolyl-3-glykosylsyrederivater som har terapeutisk verdifulle egenskaper
TW509572B (en) A pharmaceutical composition for use in stimulating neurite growth
US20200352920A1 (en) Combination therapy for the treatment of mastocytosis
US20080057124A1 (en) Indolyl-3-glyoxylic acid derivatives having therapeutically valuable properties
EP2263694B1 (en) Antitumor agent comprising the histone deacetylase inhibitor FK228 and the topoisomerase II inhibitor doxorubicin
WO2012012282A1 (en) Bifunctional rho kinase inhibitor compounds, composition and use
WO2001060370A1 (en) Remedies for endothelin-induced diseases
EP3672593B1 (en) Medicaments for the treatment of vasoconstriction related diseases or disorders
US20030158247A1 (en) Pharmaceutical composition comprising a sodium hydrogen exchange inhibitor and an angiotensin converting enzyme inhibitor
CA3202315A1 (en) Use as selective agonist of malanocortin-4 receptor
EP3458040B1 (en) Combination of pure 5-ht6 receptor antagonists with nmda receptor antagonist
US11730741B2 (en) 6-chromanol derivatives for use as a medicament
CN101305990B (zh) Edg受体结合剂在癌症中的应用
CN109096251A (zh) 具有组胺受体双重拮抗活性的化合物及用途
JP2007505036A (ja) フェニルカルボキサミドとβ−アドレナリン性受容体遮断剤の組み合わせおよびそれらの心房性不整脈の処置のための使用
WO2022164901A1 (en) Enhanced anti-proliferative and antitumor immune effects of mitochondria-targeted hydroxyurea
US20170224830A1 (en) PAK1-Activation Blocking Compounds, Preparation Thereof and Methods of Use
JPH02237925A (ja) ヒト及び獣医学的医療における徐脈及び除脈型不整脈の治療に対する、１１―位置換５，１１―ジヒドロ―６Ｈ―ピリド〔２，３―ｂ〕〔１，４〕―ベンゾジアゼピン―６―オン類の使用

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees